Occurring in 1−10% of all melanoma patients, it is associated with several high‐penetrance susceptibility genes, most commonly cyclin‐dependent kinase inhibitor 2 A (CDKN2A) in 20−40% of FM cases.1 The gene discussed is CDKN2A; the disease is melanoma.